Bayer says Nexavar misses target in liver cancer trialReuters UKFRANKFURT (Reuters) – Germany’s Bayer said a Phase III trial of cancer drug Nexavar as an adjuvant therapy for liver cancer did not meet its main target. “We are disappointed that the trial did not meet its primary endpoint,” said Joerg Moeller, member of the …Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as …Wall Street Journalall 2 news articles …read more
Via: Google USA
Bayer says Nexavar misses target in liver cancer trial - Reuters UK
Real Estate of Cebu
